Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 584-588

  Rossetti, Andrea O ^a   Jeckelmann, Sandrine ^a   Novy, Jan ^a   Roth, Patrick ^b   Weller, Michael ^b   Stupp, Roger ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Epilepsy; Glioma; Outcome; Seizure; Treatment

Indexed keywords

ETIRACETAM; PREGABALIN;

ADULT; ANXIETY; ARTICLE; BLURRED VISION; BRAIN TUMOR; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DEPRESSION; DESQUAMATION; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; IRRITABILITY; LEUKOCYTE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TUMOR GROWTH; WEIGHT GAIN;

EPILEPSY; GLIOMA; OUTCOME; SEIZURE; TREATMENT;

ANTICONVULSANTS; BRAIN NEOPLASMS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PIRACETAM; PROGNOSIS; SURVIVAL RATE;

EID: 84896950338     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not170     Document Type: Article

References (33)

1. Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1(Suppl 1):S27-S33.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453-468.
3. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 2005;65(2):212-215.
4. Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol. 2010;23(6):603-609.
5. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-430.
6. Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010; 10(5):663-669.
7. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156-1164.
8. Weller M, Stupp R,WickW. Epilepsymeetscancer:when,why,andwhat to do about it? Lancet Oncol. 2012;13(9):e375-e382.
9. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev. 2011;(8):CD008586.
10. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861-9866.
11. French J, Edrich P, Cramer JA. Asystematic reviewof the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001;47(1-2): 77-90.
12. Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med Wkly. 2002;132(29-30):425-426.
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
14. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse. 2002;45(3):171-190.
15. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-18.
16. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46(9):1407-1413.
17. Ramsay RE, Perucca E, Robbins J, Barrett JA, Spiegel K. Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia. 2009;50(8):1891-1898.
18. Perucca E. The clinicalpharmacokinetics of thenewantiepileptic drugs. Epilepsia. 1999;40(Suppl 9):S7-S13.
19. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-472.
20. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-122.
21. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0; 2006. http://ctep.cancer.gov/protocol development/electronic-applications/docs/ctcaev3.pdf. Accessed November 15 2013.
22. Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol. 2011;104(1):205-214.
23. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg. 2009;111(2):171-173.
24. Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol. 2010;67(3):343-346.
25. Bahr O, Hermisson M, Rona S, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien). 2012;154(2):229-235; discussion 235.
26. Usery JB, Michael LM 2nd, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010;99(2):251-260.
27. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009;93(3):349-354.
28. Maschio M, Dinapoli L, Sperati F, et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disord. 2012;14(4):388-397.
29. Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry. 2006;77(1):101-103.
30. YuenAW, Singh R, Bell GS, et al. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009;87(2-3):120-123.
31. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
32. Helmstaedter C, Fritz NE, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav. 2008;13(3):535-541.
33. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3): 424-429.